Recently acquired Westlake Labs life science campus to grow lab and office space

Westlake Labs’ modular lab space, designed by Gray Matter with veteran life science architects and engineers, is adding 35,000 square feet of lab and office space to its campus.

A seven-acre life science campus in the Conejo Valley’s Westlake Village is adding 35,000 square feet of speculative lab and office space after being acquired for $18 million earlier this year.

The 100,000-square-foot Westlake Labs campus, purchased earlier this year by Argosy Real Estate Partners and Graymark Capital's life sciences branch Gray Matter, is giving the life science industry deeper roots in the Conejo Valley, where a biotech hub has been steadily forming for years

Formerly the headquarters for Anthem Blue Cross, the two-story building at 120 Via Merida will be converted from a Class A corporate headquarters into a life science space. Part of the building will be built out for one or two tenants, with the property split in half for a lab and office space. 

Graymark and Argosy tapped BAM Creative, ACO Construction Management and HITT Contracting to design, engineer and construct the 35,000 square feet of lab/office space, which is slated for completion in the first quarter of 2024.

CBRE Group brokers Tom Dwyer, Caroline Bigelow, Jeff Pion and Andrew Riley are marketing Westlake Labs for future tenants. The campus aims to present opportunities across every facet of the life science industry, from mature life science companies to startup ventures and academic institutions. 

Westlake Labs’ modular lab space, designed by Gray Matter with veteran life science architects and engineers, fits an adaptable range of tenant uses, all on a campus with indoor and outdoor amenities.

The campus adds to the Conejo Valley's growing life science hub, joining more than 30 life science companies such as Amgen, Dantari, Takeda and Westlake Village BioPartners.

READ FULL ARTICLE HERE

Previous
Previous

Nurses: One Of Life Sciences' Most Valuable Assets

Next
Next

'The pieces are starting to come together:' Biocom CA exec dissects L.A. life science industry